Previous 10 | Next 10 |
Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burn i of €...
- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRAS G12C Cancers - FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRAS G12C - FMC-376 has the potential to transform patient outcomes wi...
2024-02-21 17:20:53 ET More on Galapagos Galapagos enters into strategic collaboration with Thermo Fisher Galapagos signs development deal with BridGene Seeking Alpha’s Quant Rating on Galapagos Historical earnings data for Galapagos Financial ...
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translatio...
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A. As previously announced, the transfer includes the entire Jysel...
2024-01-08 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-04 16:09:09 ET More on Galapagos Galapagos: Navigating Uncharted CAR-T Waters With A Cash Compass Galapagos signs development deal with BridGene Galapagos to transfer Jyseleca business to Alfasigma For further details see: Galapagos enters into st...
Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos’ point-of-care CAR-T product candidate in the San Francisco area Agreement follows previously announced collaboration with Landmark Bio for decentralized CAR-T manufacturing in the Boston are...
2024-01-03 16:39:19 ET More on Galapagos Galapagos: Navigating Uncharted CAR-T Waters With A Cash Compass Galapagos NV 2023 Q3 - Results - Earnings Call Presentation Galapagos NV (GLPG) Q3 2023 Earnings Call Transcript Galapagos to transfer Jyseleca business ...
Strategic collaboration and licensing agreement further strengthens Galapagos’ growing early-stage pipeline in oncology precision medicine Collaboration leverages Galapagos’ expertise in small molecule drug discovery and development with BridGene’s innovative discover...
News, Short Squeeze, Breakout and More Instantly...
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announces that all resolutions proposed at the c...